Polymorphisms in COL4A3 and COL4A4 genes associated with keratoconus by Štabuc-Šilih, Mirna et al.
Polymorphisms in COL4A3 and COL4A4 genes associated with
keratoconus
Mirna Štabuc-Šilih,1 Metka Ravnik-Glavač,2 Damjan Glavač,2 Marko Hawlina,1 Mojca Stražišar2
(The first two authors contributed equally to this work)
1Eye Hospital, University Medical Centre, Ljubljana, Slovenia; 2Department of Molecular Genetics, Faculty of Medicine, University
of Ljubljana, Slovenia
Purpose: Alterations in collagen type IV, alpha-3 (COL4A3) and collagen type IV, alpha-4 (COL4A4) genes may be
responsible for a decrease in collagen types I and III, a feature often detected in keratoconus (KC). To evaluate the
significance of alterations in COL4A3 and COL4A4 genes in KC patients, we screened both genes and estimated the
significance of polymorphisms in Slovenian patients with KC.
Methods: The study included 104 unrelated patients with KC and 157 healthy blood donors. Diagnosis was established
by clinical examination, electronic refractometry, and keratometry. DNA was extracted from blood, and gene exons were
amplified by PCR. Non-isotopic high-resolution single-stranded conformation analysis (SSCA) was used to screen
COL4A3 and COL4A4 genes, and migration shifts detected by SSCA were subsequently sequenced. For statistical
evaluation, control blood donors were chosen according to age, sex, and not having blood relationship. Neither patients
nor control blood donors chosen for statistical analysis were in blood relationship. We used Fisher’s exact test for statistical
evaluation, with p<0.05 considered significant.
Results: We detected eight polymorphisms in the COL4A3 gene and six in the COL4A4 gene. Allele differences in D326Y
in COL4A3 and M1237V and F1644F in COL4A4 are significantly distinctive of KC patients (Fisher’s exact test, p<0.05).
When analyzing different genotypes under three models (dominant, recessive, and additive), we established that P141L,
D326Y, and G895G in COL4A3 and P482S, M1327V, V1516V, and F1644F in COL4A4 have significant differences in
genotype distribution between KC patients and the control group.
Conclusions: This is the first mutational screening of COL4A3 and COL4A4 genes in KC patients to establish the status
of these genes and compare them to a control population. Analysis of COL4A3 and COL4A4 revealed no mutations related
to KC patients, but specific genotypes of seven previously described polymorphisms are significantly associated with KC
under dominant, recessive, or additive models. Differences in the expression of type IV collagen in previously published
data about chromosomal instabilities in the regions in which the analyzed genes were mapped and our data indicate a
probability that some of the polymorphisms we detected could be related to KC.
Keratoconus  (KC)  is  a  noninflammatory  progressive
thinning disorder of the cornea that leads to progressive mixed
myopic  and  irregular  astigmatism  [1].  The  estimated
incidence of KC is between 1 in 500 and 1 in 2,000 in the
general population [1]. KC occurs in all ethnic groups, with
no significant gender difference. The age of onset is puberty,
and KC is progressive until the third to fourth decade of life
when  it  usually  arrests.  It  is  the  major  cause  of  cornea
transplantation in developed countries. Although the cause of
KC is unknown, there are several lines of evidence suggesting
a genetic component. These include a positive family history
in 6–10% of KC cases [1,2] and its higher concordance rate
in monozygotic twins [1,3]. Although the disease has been
reported  to  exhibit  familiar  patterns  and  an  autosomal
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recessive mode of inheritance has been postulated, most cases
appear  to  be  sporadic  [4,5]  Hereditary  KC  is  inherited
dominantly  or  recessively,  but  families  are  frequently
diagnosed  with  autosomal  dominant,  which  presents
incomplete penetrance of the disease and variable expressivity
[5]. The underlying biochemical processes and their cause
remain  poorly  understood.  By  far  the  most  common
presentation of KC is as an isolated sporadic disorder, but a
positive association between KC and many conditions has
been suggested, including atopy, eye rubbing, wearing hard
contact lens, and cardiovascular disease (especially mitral
valve  prolapse)  as  well  as  some  rare  genetic  disorders,
connective tissue disorders, pigmentary retinopathy, Marfan’s
syndrome, Noonan’s syndrome, Apert’s syndrome, Ehlers-
Danlos syndrome, and Down syndrome [1,6].
The major protein in the cornea is collagen, and several
types of collagen have been identified by biochemical and
immunochemical methods [7]. Corneas from patients with KC
contain reduced amounts of total collagen proteins, [8] and
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2848alterations  of  the  extra  cellular  matrix  and  basement
membrane are characterized mostly by a decrease in types I
and  III  [9].  The  changes  in  the  orientation  of  collagen
molecules, which are followed by rearrangement of collagen
fibrils, also alter the shape and transparency of the cornea
[10,11]. A knockout mouse model has shown that disruption
of  the  genes  encoding  α1  (COL8A1)  and  α2  chains
(COL8A2) of type VIII collagen leads to structural changes
similar to the clinical presentation of keratoglobus [12]. KC
has not been associated with mutations in type VIII collagen
genes [13], although a relation between COL8A2 mutations
and dystrophic corneal disorders has previously been reported
[14,15].  Results  from  imunohistochemistry,  in  situ
hybridization, and expression arrays show that several other
types of collagen are differentially expressed and have an
active role in wound healing processes. Collagen molecules
that are differentially expressed in keratoconus corneas are
types  XII,  XIII,  XVIII,  and  XV,  but  there  are  no  known
relations between mutations and expression levels for those
genes  [16,17].  Upregulation  of  collagen  type  XV  and
downregulation of collagen type IV in KC corneas, observed
by Bochert et al. [18] and Stachs et al. [19], showed the
putative role of those types of collagen in KC. Types XIII,
XV, and XVIII collagen were found to be expressed in basal
corneal cells and may have a role in the adhesion of the corneal
epithelial cells to each other and to the underlying basement
membrane [16,19].
Type IV collagen is found only in basement membranes
where it is the major structural component. Mariyama et al.
[20] mapped the collagen type IV, alpha-3 (COL4A3) and
collagen type IV, alpha-4 (COL4A4) genes to the same region,
2q35-q37, but on opposite strands and transcribed in opposite
directions [21]. The COL4A3 gene spans 250 kb and consists
of 51 exons; the COL4A4 gene is shorter, spanning 113 kb and
consisting of 48 exons [20,22]. COL4A3 and COL4A4 are two
of six α chains that form heterotrimeric type IV collagen
molecules  [20,23,24].  Type  IV  collagen  is  expressed  in
corneas and implicated in Goodpasture and Alport syndromes,
which are often accompanied by eye abnormalities, but their
involvement in eye disorders is still unknown [22,24-26].
COL4A3 has already been implicated in the pathogenesis of
polymorphous corneal dystrophy-3 [27,28], and both genes
are  reported  to  be  differentially  expressed  in  keratoconus
corneas [18,19]. Results from the study published by Stachs
et  al.,  favored  collagen  type  IV  as  a  candidate  gene  in
keratoconus  pathogenesis  [19].  Because  a  change  in  the
expression levels of collagen type IV α-3 and α-4 chains were
observed in corneas affected by KC, we investigated whether
there are alterations in COL4A3 and COL4A4 related to KC
patients.
METHODS
Patients: The genetic study included 104 unrelated patients
with KC and 157 healthy blood donors as a control. After
examination of the patients (clinical examination, electronic
refractometry,  and  keratometry)  and  precise  personal
anamnesis, an unrelated cohort of patients diagnosed with KC
was selected for this study. We excluded patients with other
ocular diseases that could influence the interpretation of the
results: blepharoconjunctivitis, keratitis, opacifications of the
lens, changes of the macula, and cup/disc ratio  (C/D) of the
optic nerve of 0.3 or more. One hundred and four patients, 65
males  and  39  females,  were  included  in  this  study  after
informed consent had been obtained and after determination
of the diagnostic and other criteria. All the patients included
in the study had no other diagnosed disease. The patients’ ages
were from 20 to 67 years (mean±standard deviation [SD]
39.1±8.2 years). For the control population we used peripheral
blood taken from 157 blood donors collected at the Blood
Transfusion Centre of Slovenia (57 women, 100 men; mean
age ± SD 37.2±10.2 years). Blood samples from patients with
KC and from healthy Slovenian blood donors were in the form
of anticoagulated blood. Blood from KC patients and controls
was obtained from the median cubital vein, on the anterior
forearm in 3 ml vacuum blood collection tubes with EDTA
K3 (Laboratorijska tehnika). Blood was stored in collection
tubes at -20 °C until the DNA was isolated. The control group
was  selected  on  the  basis  of  age,  nationality,  and  gender
comparable  with  the  KC  patients.  There  were  no  blood
relations among individuals in the control group or between
individuals in the control group and individuals in the KC
group, and control individuals had not been diagnosed with
KC. The National Medical Ethics Committee of the Republic
of Slovenia approved the study.
DNA extraction and mutational screening: Genomic DNA
was  isolated  from  peripheral  blood  lymphocytes  by  salt
precipitation. After the blood samples were thawed, saline-
sodium citrate buffer (Merck) was added, mixed on Vibromix
(Tehtnica), and the samples centrifuged (12,000 rpm for one
minute, centrifuge 5415R; Eppendorf). The top portion of the
supernatant was discarded and saline-sodium citrate buffer
(Merck) was added, mixed, and again mixture centrifuged
under same conditions. Then was supernatant discarded and
pellet re-suspended in a solution of sodium dodecyl sulfate
detergent (10 % SDS; Sigma-Aldrich) and 5 µl of proteinase
K  (20  mg/ml  H2O;  Sigma-Aldrich).  The  mixture  was
incubated at 55 °C for 1 h (Thermomixer comfort; Eppendorf).
After incubation was DNA treated with a phenol/chloroform/
isoamyl alcohol solution in ratio 25:24:1 (Sigma-Aldrich). 
After centrifugation (12,000 rpm for 1 min, centrifuge 5415R;
Eppendorf) was the aqueous layer removed to a new micro
centrifuge tube (Costar) and two consecutive DNA ethanol
precipitations followed; first one with 100 % and second one
with 80 % ethanol (Merck). DNA was re-suspended in 10:1
Tris-EDTA  buffer  (Sigma-Aldrich)  between  both
precipitations. After the second precipitation the pellets were
dried at room temperature followed by addition of 10:1 Tris-
EDTA buffer (Sigma-Aldrich). The mixture of DNA and Tris-
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2849EDTA buffer (Sigma-Aldrich) was re-suspended with mixing
and incubation at 55 °C overnight (Thermomixer comfort;
Eppendorf). Amplifications of COL4A3 and COL4A4 were
performed by PCR. For the PCR reaction we used the primers
(Operon)  previously  described  by  Heidet  et  al.  [29]
(COL4A3;Table 1) and Boye et al. [22] (COL4A4; Table 2).
Screening for changes in PCR products was performed
with single-stranded conformation analysis (SSCA) for each
PCR fragment of a given set of samples from patients and
healthy blood donors. Large glass plates (35×40 cm) were
used to obtain maximum sensitivity. The shorter plate was
coated  with  Repel-Silane  (Merck).  The  longer  plate  was
coated  with  Bind-Silane  (20  ml  of  g-
methacryloxypropyltrimethoxysilane,  5  ml  of  bi-distilled
H2O, 5 ml of 100 % ethanol; Merck), then warmed to 50 °C
for about 30 min and cooled to room temperature. A 3 ml
TABLE 1. OLIGONUCLEOTIDE PRIMERS AND PCR TEMPERATURES USED FOR SINGLE-STRANDED CONFORMATIONAL ANALYSIS AND SEQUENCING OF THE COL4A3 GENE [29].





EX 1 CGGACTCGCCCAGGCTCTGA GACGCGTGGAGGAGGGATG 176 62
EX 2 AACAAAACCCTTTCTCTT AAGCAGTATTAGGGTTTGTT 113 49
EX 3 TGTGTGTTTCTCACCTCGT GATTTTCCAAGCTTGCAG 151 54
EX 4 TTTCTTTTTTCACTTGAATCT ACGATCAGGGTGGACTG 99 50
EX 5 CCCCCTCCTTTTTCCTATGT TTTCTAGCTACGGATTTTTC 102 45
EX 6 CCTCATTGAGACTTGTTCT TCATCTTCTGTGTGAAAAGT 116 42
EX 7 AATAATAAGAAACTTTGTATGT GGGAATTAGGCATGCAAA 106 49
EX 8 GTTGTTCATAGGTTGCTTTT TCAGTGACAGCATTCCAC 83 46
EX 9 GATGTTTGATGAACTTCTTC ATAGGGACCTTCTCTGAA 134 52
EX 10 TACTCTTATTCTTCTCTCAA CTGTAGCAAGGATGACT 117 49
EX 11 GTGATTTTCATTTGTGGATT AGCTGTTACATCATATGAACT 93 48
EX 12 AATAATTTGGTTTTGTGTT CCTGCTAATAAAACATAGTA 100 44
EX 13 ACTCCTGAGTGTTTTTGT TAATCATAAAATCGCAGA 126 49
EX 14 TTGTAACAATGTTGAACTGT ATGGGGACAATATAACTTTA 124 50
EX 15 ATAAAATTTGACATGGCTCT GACTAATCAAAACTGCACAT 133 49
EX 16 TTTCATGTTTTTGATTTGTT TGACATTTTTACTACCTCCA 116 46
EX 17 GACCCATTTCTTTTTGTTCT AAAATAGGCTATTAGGGAGA 110 48
EX 18 CACAATTTGTAAATGTCTT GATATTGTCTTTAATCACAC 94 46
EX 19 TCTGTATTTGTTTCTTTCTC AAATGCTTTAGGAAGAAAT 141 52
EX 20 TTATATCTTTCTAAGCCATT CCTTTGTAATAGCATTTCTA 125 47
EX 21 TCTCCATTGTGCAATTTTTA CTAAGCTGTGAGGAGGGTTT 367 53
EX 22 ATTGTCTTTGGTGCTGTAT GGCTTATCCTAATACAACAT 156 49
EX 23 AAGTAATGCTAGTATGCTCTC TGTGCTTGCAAAAACACT 162 49
EX 24 TAGTTAATAATTCGTTGA AAGATTTAAAAACATGAA 121 44
EX 25 ACAGATTCATTTGTGTACTA GAGGGTAAAGTTGCTAAATA 234 54
EX 26 ATTCAAACACATTCCTGT GGACTGGAAAGAAAACTAA 219 51
EX 27 ATCTTATGACCACAAATTTC CAGATTTGGCAGAGGATA 142 54
EX 28 AGATGCATATGTGTATTTGT CTTCTAAATATCCACAACAA 182 44
EX 29 CTAATCCTACAACAATGTTT TTCTGTGATAGCTTGAATTT 164 47
EX 30 ATAGTAATAACACAATTTCT GAGAAAAGTAATGACACT 209 45
EX 31 CCTGGGTATATACTTGTGCT ATGTCTCCTGCCCTTCTGG 191 52
EX 32 GGAAAGCATTTGTGGGTTA ACAGAGCCACCTTAAGAAGA 276 52
EX 33 TGCTTTGTGTTAATTTGTTT TCCTGCTATTTAGAAAGACA 149 52
EX 34 AAGGACCTGATGTTGTTACT TCTGATGTCCTGATTCCA 202 52
EX 35 TTCTTGTTAATACCTGGTTT TGATATTTTTCTATTTGAGA 160 49
EX 36 CAGGGCAATAACTACTTA GCTCATAACAGGACCTTA 146 50
EX 37 TACTCTATGTTTTCCCCCTA TCCACCACTAAAATGTAAAT 206 52
EX 38 TATGAGAATTTTAAAGGTAT TCCAGCTTTTAGAATTGTAA 195 48
EX 39 GGTGATCTTTTTTCTTCCTT CCCACATGAAAAGGAAAAAG 160 50
EX 40 GGGGTTTTGGGTTTTTTT ACGGATCAAAGATAATGAGCA 156 52
EX 41 CAATTATTAACATGCCAAGA TACATTAGGACAGGGAAGAA 112 50
EX 42 AAAGAAACTTATTAAGCCTT TTGTTATTTTATGCTGTTTA 253 52
EX 43 ATACTGACAGACTTTTCAT TAATAATGAGTCAAAATAAT 191 50
EX 44 GTTTTGCTCCCTTTATTTGA ATATAAAGAGCAATGCACAA 129 51
EX 45 GGAAACCCATTGATCTAAGT ACCTTTCTTCATTGACAGCA 164 51
EX 46 TGAGGCCATCATCTTCTTCT TCCTAGTGATCCAAGTCAAT 199 50
EX 47 CCACCTTACTTTTCATCCTAT ACTTCTTCGGTGAGGAAAC 190 59
EX 48 CTTTGAAAAAACGAGTTTAAG TTACAATCTGCATGTGGAA 324 61
EX 49 CTAGTAACGATGCTGAAAATAAC TCACTTGGTCCCATTGTAA 284 54
EX 50 TTCCCTTGTAATGGAATGAAA CACATTTTACCCAGCACAAT 271 52
EX 51 AACCCCAATGGACAGAGTGTT TGAATAGTTCTGCAATTGAGT 272 63
EX 52 CAGCAAAAATTCCCTTTTATG TGTTCTTTAGGATGAAAAAT 190 47
In the table, Length represents length of the PCR product in base pairs (bp) and Annealing temp represents the annealing
temperature of the primers used for PCR reactions.
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2850portion of PCR product was mixed with 10 ml of loading
buffer (95% formamide, 5 mM NaOH, 0.1% bromophenol
blue, and 0.1% xylene cyanol, Sigma-Aldrich). Samples were
heated to 95 °C for 2 min and then cooled in ice water. Each
PCR  product  mixed  with  loading  buffer  was  loaded  onto
polyacrylamide gels (35×40×0.04 cm). Combs with 96 teeth
were  used  for  loading  samples  and  10%  acrylamide  gels
(Merck)  with  2.6%  bis-acrylamide  (Merck)  to  analyze
multiple exons at once. Gels were run at 4 °C in 1× TBE
(50mM Tris-borate, pH 8.3, 4 mM ethylenediaminetetraacetic
acid; Merck). For DNA visualization, we used the optimized
method of Heukeshoven and Dernick [30] with most phases
at 55°C. Silver staining (Merck) was performed on thin gels
(0.4  mm)  fixed  on  the  larger  glass  plate.  Samples  with
different migration shifts were chosen for sequencing, which
was done with a BigDye Terminator Ready Reaction Mix
(Applied Biosystems). Sequences were purified, dissolved,
and  analyzed  on  an  ABI  PRISM  310  Genetic  Analyzer
(Applied Biosystems; Figure 1 and Figure 2).
Deviations of the Hardy-Weinberg equilibrium: Deviations of
the Hardy-Weinberg (H-W) equilibrium were calculated with
the χ2 online test with 1 degree of freedom (DF=1) for each
TABLE 2. OLIGONUCLEOTIDE PRIMERS AND PCR TEMPERATURES USED FOR SINGLE-STRANDED CONFORMATIONAL ANALYSIS AND SEQUENCING OF THE COL4A4 GENE [22].





EX 2 TCTGGAAGAGAAGACTGGCA AAGCAGGCAATCACACTGA 153 54
EX 3 TGTTTAAATTAATCTGCGTT GCAACCAGAGCTAGTG 105 48
EX 4 CGATGAGTACTGGTATACTA ATGCTGCCCATGTTGGTCTT 152 50
EX 5 ACCCCCATTTCTTTTTAATC GGTGAGTCTTTCATGTGAAT 208 54
EX 6 TCTCTTTGTTTTATTTTCTG GATGAGTACTTCTGCCTTTT 127 47
EX 7 TTTCGCAAAAATGCTTCACT CCACAGGGCCTGTTCACTTA 211 60
EX 8 TACTGAAATGGTAATACGCT CATGGGCTTACCTATTTGGA 184 48
EX 9 TGTGTGGACTTAAAGCGATG TAGAGCCTGCTCAGGAGACT 96 53
EX 10 TTGGGTAACAGATGCACTGA AAGGGATCACATCAGCAGTG 129 55
EX 11 TTGTGTTTTTTTCTCCCTTG TTTCATTGTTCAGGGCTCTA 109 50
EX 12 AGCCAGAAGTCTTAATTGCT TCACCATTTGCTCCTCAGAG 156 54
EX 13 GGGTGGAAACCTTCAAAACA TACTTTCCAAGGTGACATAT 179 50
EX 14 GGAGATGGAATTCAGTATGT AAAGACCATGAGAAATAACA 197 53
EX 15 CCCCTCTAAATGTTGTCATC TTTGAGCTTGTGGGACTACT 180 54
EX 16 AATGATGCACTGAGCTGGTT GCACGCAACAGTACAACTTC 200 53
EX 17 ATTTGTCACCCCGTCACTTT GAATGATTCCTGGCAATACT 201 50
EX 18 CCAGGCAACATGAGTAAAAT TGGAGGAACTGAATAGGAAC 155 50
EX 19 TGCACATACCATTTGTTTAT CCAGGGCACATCAGGGCATC 175 50
EX 20 TTCTTCTACAGAGACGTTT TGCTAATGGATATGAATAAG 259 52
EX 21 TATAGAAGACAGTCAGAAAA TAGAAATTCTACCTTTGGTG 181 50
EX 22 AAATATGACAAATCTGCCAT GGAAAGATGACTGGTAAGAG 227 50
EX 23 TGATCCATCACAATTAACCT CAGGGAGTTAAGTGATTGAT 149 53
EX 24 ACTTTACCCTCTGCTGATAA GGGAAATAGTTGTTTGTATG 223 50
EX 25 GACATTCAGTGGTTGGTAAT TAAACACTTGTACCCCAAAG 280 60
EX 26 TCAGTTATGTGAATGCCGCT TGGGAAGTATATAAGACAGT 147 50
EX 27 TGAGTCTGTGTTTTGTTTTT AAAAAAAAAAACCTCAC 210 52
EX 28 ATTGGTTCTATACTTGCACA TCTATGCACCAAAAGGACAG 309 54
EX 29 TGGGCCATCTGTATAGTTTT TAATAGTAAGTAGGGTAAGC 269 57
EX 30 GCCTTCACACACTGTGGTCA ATGGGAGGACATCATGGAAA 240 55
EX 31 TCCTAAAACTTTATGCTCTC TCAAATACCAGAAACAAATG 221 53
EX 32 CCTGTTCATTTTGTTCTTGC TGTCAACTTATTTGATATGG 187 57
EX 33 TTTCAGCAGAGACCTGTAAC AAGAACAGAAAGGTTTTATT 271 52
EX 34 GTTGTGCATGTGCCATTTGT GATGGCTTCTGTATCTCC 154 50
EX 35 TGAGACCAAATTAAATTGTC TCATTGCCAGCTAGAAGTAA 210 52
EX 36 CAAACGGCAACTCTGATGTT AGTGCTCAGGAAGTCTCCAG 183 55
EX 37 TATCTGGCCATCTGCAAAAC TTGTGGGATGGGCTTCATTT 173 55
EX 38 GCGTTTGTGGCTAGAGTGAG GAACCATGGACTGAAGCTCAG 190 57
EX 39 AGGCACTATAACAGGGACAAGA GGAGTAACGTAAACCTTCCA 256 60
EX 40 ACCTTCCAAATGCAATGAGG CATCCTTTGTCATGATTCTCTC 184 53
EX 41 TTTTTGTCTCTTCTCTGTGG AGTTATTCACATATTACTTA 218 48
EX 42 GCCCTCATTTTTATGTTTTG GTTGGAAGCTCACCTGGAAG 153 54
EX 43 GACTGGCCTCGTTTG TTAATATCCTTACAGCACCC 180 50
EX 44 ATTACACAAGCGGTGATTCC TGGCTCCTTCTGGTCCTCTC 118 56
EX 45 CACCAGCATCATAAACTT AGGTTTACAGTGTCAGAGAA 186 53
EX 46 AGTGCCAGAACAGAGGTGCT GGAGATGGGCGATCCTGTA 297 57
EX 47 ACACCAGCTGTCTCTTCTTC TGAATGAGCCAGGGTTT 353 57
EX 48 GTGTGTGTCTGAGCCCTAAT TGGTGAATTTCGCATTCT 322 50
In the table, Length represents length of the PCR product in base pairs (bp) and Annealing temp represents the annealing
temperature of the primers used for PCR reactions.
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2851polymorphism found in KC patients and control groups. By
the use of a χ2 table, with DF=1, the limits for maintaining a
null hypothesis (that the observed data has Hardy-Weinberg
proportions) were obtained. If the result equaled or was less
than  0.05  (5%  limits),  we  concluded  that  there  was  no
statistical deviation from the Hardy-Weinberg equilibrium in
our data (Table 3).
Associations between allele and genotype frequencies: The
magnitudes  and  directions  of  associations  between  the
polymorphisms found and KC patients were determined using
Fisher’s exact test with a two-sided p value. Fisher’s exact test
was chosen because it is based on exact probabilities from a
specific distribution and is the preferred tool over the χ2 when
comparing  small  data  samples  and  a  large  sample
approximation would be inappropriate. A two-sided p value
was  calculated  to  determine  the  significance  of  the
relationship,  and  a  value  of  p<0.05  was  considered
statistically  significant.  Significant  relationships  for  each
allele or genotype group between KC patients and the control
group are summarized as odds ratio (OR) and relative risk
(RR; Table 4).
The  significance  of  genotype  frequencies  for  each
polymorphism found in the two-tested groups (patients and
controls) was tested in two models, dominant and recessive.
A  dominant  model  was  constructed  on  the  basis  of  a
presumption that at least one allele would be changed. We
therefore combined the number of heterozygous genotypes
with  the  number  of  homozygous  genotypes  for  each
polymorphism  genotype  and  analyzed  whether  the
representation  of  genotypes  was  significantly  different
between cases and controls for each polymorphism (Table 5).
A  recessive  model  was  constructed  on  the  basis  of  a
presumption that both alleles would be changed. Therefore the
number  of  homozygous  genotypes  against  combined
heterozygous and homozygous genotypes for another allele
were  compared  for  each  polymorphism  and  whether  the
representation  of  genotypes  was  significantly  different
between  cases  and  controls  for  each  polymorphism  was
analyzed (Table 5). An additive model was constructed to test
the significances between KC patients and the control group
for all genotypes in detected polymorphisms (Table 6). For
statistics we used the Fisher’s exact test, and when the two-
sided value was less than 0.05, the results were summarized
as an OR and RR. All statistical analyses were performed
using SPSS ver.14 (SPSS Inc.).
SIFT and PolyPhen predictions for polymorphisms causing
amino  acid  substitution:  The  potential  impact  of
polymorphisms causing amino acid substitution was assessed
with  two  analytic  tools:  SIFT  and  PolyPhen.  SIFT  is  a
sequence  homology-based  tool  that  sorts  intolerant  from
tolerant  amino  acid  substitutions  and  predicts  whether  an
amino acid substitution in a protein will have a phenotypic
Figure 1. A: Three different PCR–single
stranded  conformational  analysis
patterns  on  one  gel,  representing
COL4A3  exons  17,  48,  and  49.  PCR
fragments  were  loaded  in  succession
from shortest to longest PCR fragment
at 30-min intervals. Exons 48 and 49 did
not  show  any  differences  in  elution
shifts; in exon 17, the different patterns
were subsequently sequenced. B: Partial
sequence of exon 17 with heterozygous
substitution D326Y (976GT). C: Partial
sequence of exon 17 with homozygous
substitution 326Y (976TT). K1 to K4
marked  patterns  are  patterns  of  three
exons (17, 48, and 49) of COL4A3 from
keratoconus patients, multiplied by PCR
and  analysed  with  SSCA.  C1  to  C3
marked  patterns  are  patterns  of  three
exons (17, 48, and 49) of COL4A3 from
controls  multiplied  by  PCR  and
analysed with SSCA. '1/1', '2/2' denote
different genotypes at position 976 (1/2
being  GT  and  2/2  being  TT)  in
COL4A3. GG genotypes, being  '1/1’
genotypes,  are  unmarked.  Single
stranded  DNA  (ssDNA)  and  double
stranded  DNA  (dsDNA)  patterns  are
marked on the side of the SSCA gel.
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2852effect. SIFT is based on the premise that protein evolution is
correlated  with  protein  function.  Positions  important  for
function should be conserved in the alignment of the protein
family, whereas unimportant positions should appear diverse
in the alignment. The SIFT tool calculates a score for the
amino  acid  substitution,  and  a  score  lower  than  0.05  is
considered  potentially  damaging  (Table  7).  PolyPhen
(Brigham and Women's Hospital, Harvard Medical School) is
a tool for predicting the possible impact of an amino acid
substitution on the structure and function of a human protein.
This prediction is based on straightforward empirical rules,
which  are  applied  to  the  sequence,  phylogenetic,  and
structural  information  characterizing  the  substitution.  The
PolyPhen  tool  uses  Position-Specific  Independent  Counts
software  to  calculate  profile  scores  obtained  from  the
likelihood of a given amino acid occurring at a position of
interest compared to background frequencies (the likelihood
of this amino acid occurring at any position; Table 7).
RESULTS
Mutational  analysis:  Mutational  analysis  of  all  exons  in
COL4A3 and COL4A4 genes did not reveal any mutations in
KC patients. We detected eight polymorphisms in COL4A3,
six  of  them  amino  substitutions  (G43R,  P141L,  E162G,
D326Y,  H451R,  and  P574L),  and  six  polymorphisms  in
COL4A4,  three  of  them  amino  acid  substitutions  (P482S,
G545A, and M1327V; Table 3, Figure 1 and Figure 2). All of
the  polymorphisms  were  also  detected  in  the  healthy
population and have previously been described as showen in
Table 3.
Hardy-Weinberg  equilibrium:  When  analyzing  the  H-W
equilibrium, we discovered that the frequencies of most of the
polymorphisms discovered deviate from expected numbers in
both KC patients and controls. In the COL4A3 gene, only three
(P141L, D326Y, and G895G) polymorphisms in the control
group and two (D326Y and P574L) polymorphisms in the KC
patient group had a p value less than the 5% limit, which was
the cut-off value for determining no statistical deviation from
the H-W equilibrium. In COL4A4, the observed frequencies
of three polymorphisms (P428S, M1327V, and V1516V) in
the control group and two (G789G and M1327V) in the KC
patient group did not deviate from the H-W equilibrium (Table
3).
Associations between allele and genotype frequencies: The
allele frequency in three polymorphisms was significantly
associated with KC patients (Table 4). P141L, D326Y, and
G895G  in  COL4A3  and  P482S,  M1327V,  V1516V,  and
F1644F in COL4A4 polymorphisms were associated with KC
patients,  either  as  genotypes  or  alleles,  with  calculated  p
values less than 0.05 (Fisher’s exact test; Table 4, Table 5, and
Table 6). Significantly represented alleles in KC patients are
976G  (D326Y,  COL4A3)  with  OR=  15.017,  3979G
(M1327V, COL4A4) with OR= 2.497, and 4932C (F1644F,
COL4A4) with OR= 1.750 (Table 4). When analyzing the
representation of genotypes for all the polymorphisms found
between KC patients and controls, we discovered that some
of the genotypes were significantly represented only in the KC
patient  group  (Table  4).  The  analysis  was  performed  in
relation to the representation of mandatory both (recessive) or
at least one allele (dominant) being changed.
In  terms  of  the  dominant  model,  genotypes  422CC
(OR=8.524)  and  976GG  (OR=30.645)  in  COL4A3  and
3979GG (OR=12.922), 4548AA (OR=1.993), and 4932CC
Figure 2. A: Three different PCR–single
stranded  conformational  analysis
patterns  on  one  gel,  representing
COL4A4  exons  9,  10,  and  42.  PCR
fragments  were  loaded  in  succession
from shortest to longest PCR fragment
at 30-min intervals. Exons 9 and 10 did
not  show  any  differences  in  elution
shifts;  in  exon  42,  different  patterns
were subsequently sequenced. B: Partial
sequence of exon 42, made with reverse
primer,  showing  homozygous
substitution  1327M  (3797AA).  The
position marked on reverse sequence is
3797TT. C: Partial sequence of exon 42,
made  with  reverse  primer,  showing
homozygous  substitution  1327V
(3797GG).  The  position  marked  on
reverse sequence is 3797CC. '1/1',’1/2’
and '2/2' denote different genotypes at
position  1327  in  COL4A4.  Single
stranded  DNA  (ssDNA)  and  double
stranded  DNA  (dsDNA)  patterns  are
marked on the side of the SSCA gel.
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2853(OR=  2.890)  in  COL4A4  are  significantly  related  to  KC
patients (Table 5). Significantly higher represented genotypes
with  the  recessive  model  are  976GG  (OR=16.545)  and
2685CC (OR=2.977) in COL4A3 and 1444TT (OR=2.788)
and 4932CC in COL4A4 (OR=1.701; Table 5).
We also discovered through analysis of both models that
some of the genotypes were significantly less frequent in KC
patients: 976TT and 2685AA in COL4A3 and 1444CC and
4932 TT in COL4A4 for the dominant model; 422TT and
976TT in COL4A3 and 3979AA, 4548GG, and 4932TT in
COL4A4 for the recessive model (Table 5). In the additive
model, genotypes 422CC, 422TT, 422CT, 976GG, 976TT,
and 2685AA in COL4A3 and 1444CT, 3979AA, 3979GG,
4548AG,  4932CC,  and  4932CT  in  COL4A4  were
significantly different between KC patients and the control
group (Table 6).
SIFT and PolyPhen predictions: PolyPhen analysis predicted
that G43R, P141L, D326Y, and P574L polymorphisms in the
COL4A3 gene are potentially damaging. All tested missense
polymorphisms in COL4A4 are predicted to be benign. SIFT
tool  analysis  gave  a  score  less  than  0.05  for  G43R  in
COL4A3 and G545A in COL4A4. Those substitutions are
predicted to affect the protein function and would not be
tolerated. All other substitutions are predicted as tolerated
(Table 7).
DISCUSSION
To our knowledge this is the first report describing the genetic
screening  of  two  type  IV  collagen  genes  in  KC  patients.
Frequent polymorphisms in affected and healthy populations
were found, but no mutations in either of the genes that could
be related to KC were discovered. Previous data have revealed
that the expression of type IV collagen is deregulated in KC
patients and that chromosome locations with genes important
in the regulation of collagen synthesis (including type IV
collagen)  are  frequently  subjected  to  aneuploidy  and
translocation  [18,31].  Given  the  identification  of  changed
amounts of collagen and no affirmative data about relations
between mutations in already researched collagen genes and
KC, we analyzed the COL4A3 and COL4A4 genes, which are
deregulated  in  KC  patients,  are  often  subjected  to
chromosomal aberrations, and could also be responsible for a
decrease in collagen types I and III, a feature often detected
in the disease [8,9,11,18,19,31].
All of the alterations found in both genes have already
been  published  in  other  studies.  When  analyzing  whether
polymorphisms  found  were  in  H-W  equilibrium,  we
discovered  that  most  of  them  were  not.  It  is  difficult  to
speculate the main reason for this, but some of the probable
causes  of  population  differences  shown  in  the  study  are
selection, small population size, population stratification, and
genetic drift. It is not rare to find that polymorphisms are in
H-W disequilibrium because of the above-mentioned reasons.
The control group was selected as described in the Methods
section. Considering the small number of some of the alleles
found, it is easy to predict that a larger sample size of controls
and inclusion of different nationalities and races could help to
meet  the  criteria  for  H-W  equilibrium,  but  the  allele
TABLE 3. DATA ABOUT OBSERVED POLYMORPHISMS IN KERATOCONUS PATIENTS AND CONTROLS WITH CALCULATED DEVIATION FROM HARDY-WEINBERG
EQUILIBRIUM.
Hardy-Weinberg CHI (p-value)
Polymorphism Exon dbSNP ref ID Cases Controls
COL4A3
G43R 2 rs13424243 0.2127 (p>0.2) 0.2928 (p>0.2)
P141L 7 rs10178458 2.1005 (p<0.2) 18.333 (p<0.0001)
E162G 9 rs6436669 1.6271 (p>0.2) 0.9575 (p>0.2)
D326Y 17 rs55703767 3.6385 (p<0.1) 11.6848 (p<0.001)
H451R 22 rs11677877 0.6282 (p>0.2) 0.8912 (p>0.2)
G484G 23 rs34019152 0.2127 (p>0.2) 0.4525 (p>0.2)
P574L 25 rs28381984 4.7767 (p<0.05) 0.8502 (p>0.2)
G895G 33 ref* 0.2376 (p>0.2) 5.8157 (p<0.02)
COL4A4
P482S 21 rs2229814 0.5769 (p>0.2) 30.0822 (p<0.0001)
G545A 23 rs1800516 0.1261 (p>0.2) 0.2928 (p>0.2)
G789G 28 rs56247709 5.0335 (p<0.025) 0.2478 (p>0.2)
M1327V 42 rs2229813 12.1981 (p<0.001) 9.1888 (p<0.01)
V1516V 47 rs2228555 0.6683 (p>0.2) 8.5342 (p<0.01)
F1644F 48 rs2228557 0.4009 (p>0.2) 1.3937 (p>0.2)
dbSNP  ref ID: identity numbers for observed variants; ref*: polymorphism is not listed in dbSNP, but was reported by Wang
et al. [34]. Hardy-Weinberg CHI (p-value): calculated chi values according to our data for cases and controls separately, and
deviation between observed and expected numbers. When p-value equals or is less than 0.05 (5%) limit, then there is no statistical
deviation from the Hardy-Weinberg equilibrium.
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found by Šlajpah et al. [32]. Even though obvious violations
to the H-W equilibrium were detected, genotypes and allele
representations for some polymorphisms statistically differ
between  groups  and  are  much  more  frequent  in  the  KC
patients than in the healthy population, which should be taken
into  consideration  when  assessing  differences  between
genotypes and phenotypes for a chosen population.
For predicting the effect of substitutions found, we used
two different tools, PolyPhen and SIFT, which predict the
possible  impact  on  the  structure  and  function  of  protein
substitutions. COL4A3 G43R, P141L, D326Y, and P574L
polymorphisms  were  predicted  to  have  an  effect  when
analyzed with PolyPhen, but SIFT predicted that only G43R
would be damaging. Out of all the substitutions found in
COL4A4, only G545A was predicted by SIFT to be damaging.
Discrepancies between predictions using different tools are
expected because the matrices and nature of assessing the
damaging effects are based differently. PolyPhen predicts the
functional effect of substitutions by determining the level of
sequence  conservation  between  homologous  genes  over
evolutionary time, the properties of the exchanged residues,
and the proximity of the substitution to predicted putative
protein domains and structural features within the protein.
SIFT predicts the functional importance of an amino acid
substitution based on the alignment of highly similar protein
sequences. Predictions rely on whether or not an amino acid
at the position of our interest is conserved in the protein
family, which can be indicative of its importance to the normal
function  or  structure  of  the  expressed  protein.  Not  all







(n=314) p-value OR RR
G43R 127G 199 301      
  127C 9 13 1.0000    
P141L 422C 172 261      
  422T 36 53 0.9059    
E162G 485A 174 262      
  485G 34 52 1.0000    
D326Y 976G 199 187      
  976T 9 127 <0.0001 15.017 7.790
H451R 1352A 193 292      
  1352G 15 22 1.0000    
G484G 1452G 199 298      
  1452A 9 16 0.8349     
P574L 1721C 118 166      
  1721T 90 148 0.4195    
G895G 2685A 137 227      






(n=314) p-value OR RR
P482S 1444C 117 182      
  1444T 91 132 0.7183    
G545A 1634G 201 301      
  1634C 7 13 0.8168    
G789G 2367G 200 302      
  2367A 8 12 1.0000    
M1327V 3979A 74 182      
  3979G 134 132 <0.0001 0.4005 0.5738
V1516V 4548A 119 184      
  4548G 89 130 0.7861    
F1644F 4932C 136 163      
  4932T 72 151 0.0028 1.750 1.409
Cases: number of alleles found in keratoconus patients, Controls: number of alleles found in healthy blood donor population,
n: number of all alleles, p-value: two sided p-value calculated with Fisher’s exact test for determining the significance between
differences in alleles found in keratoconus patients and controls for each polymorphism, OR: odds ratio, RR: relative risk. OR
and RR are shown only for polymorphisms for which allele differences are significant (p-value less than 0.05).
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Allelesubstitutions predicted to affect protein function are involved
in disease development and/or progression, especially in the
complex  diseases,  such  as  KC.  Still  in  the  absence  of
functional data, it is advantageous to use predictive tools to
identify substitutions that would more likely affect wild-type
protein  function;  nevertheless  differences  in  results  using
TABLE 5. GENOTYPE REPRESENTATION AND ASSOCIATIONS UNDER DOMINANT AND RECESSIVE MODEL BETWEEN KERATOCONUS PATIENTS AND CONTROLS.






(n=157) p-value OR RR p-value OR RR
G43R 127GG 95 144 NC NC NC 1.0000    
  127CC 0 0 1.0000     NC NC NC
  127GC 9 13            
P141L 422CC 69 116 0.0177 8.524 5.399 0.2115    
  422TT 1 12 0.2115     0.0177 0.117 0.1852
  422CT 34 29            
E162G 485AA 71 111 0.2489     0.6821    
  485GG 1 6 0.6821     0.2489    
  485AG 32 40            
D326Y 976GG 96 66 <0.0001 30.645 17.013 <0.0001 16.545 7.333
  976TT 1 36 <0.0001 0.060 0.136 <0.0001 0.033 0.058
  976GT 7 55            
H451R 1352AA 89 135 NC NC NC 1.0000    
  1352GG 0 0 1.0000     NC NC NC
  1352AG 15 22            
G484G 1452GG 95 141 NC NC NC 0.8306    
  1452AA 0 0 0.8306     NC NC NC
  1452GA 9 16            
P574L 1721CC 28 41 0.5039     0.3853    
  1721TT 14 32 0.3853     0.5039    
  1721CT 62 84            
G895G 2685AA 44 76 0.0399 0.336 0.589 0.3752    
  2685CC 11 6 0.3752     0.0399 2.977 1.698
  2685AC 49 75            







p-value OR RR p-value OR RR
P482S 1444CC 31 36 0.0147 0.360 0.597 0.2474    
  1444TT 18 11 0.2474     0.0147 2.788 1.674
  1444CT 55 110            
G545A 1634GG 97 144 NC NC NC 0.8130    
  1634CC 0 0 0.8130     NC NC NC
  1634GC 7 13            
G789G 2367AA 97 145 0.3985     1.0000    
  2367TT 1 0 1.0000     0.3985    
  2367AT 6 12            
M1327V 3979AA 5 62 0.0897     <0.0001 0.077 0.146
  3979GG 35 37 <0.0001 12.922 6.838 0.0897    
  3979AG 64 58            
V1516V 4548AA 32 53 0.0362 1.993 1.561 0.6861    
  4548GG 17 44 0.6861     4 0.502 0.641
  4548AG 55 60            
F1644F 4932CC 43 46 0.0038 2.890 2.053 0.0469 1.701 1.362
  4932TT 11 40 0.0469 0.588 0.734 0.0038 0.346 0.487
  4932CT 50 71            
Significant differences are shown in bold. Cases: keratoconus patients, Controls: healthy blood donors, n: number of individuals,
NC- not calculated, Genotype: Genotypes found representing each polymorphism in cases and controls. Fisher’s exact test was
used for statistics. Differences between genotypes are significant when two-sided p-value (p-value) is less than 0.05. OR: Odds
ratio, RR: relative risk. OR and RR are shown only for genotypes with significant differences (p-value less than 0.05). Dominant
model column shows Fisher’s test results calculated from the sum of the number of individuals with homozygous and
heterozygous genotypes compared to the number of individuals with another homozygous genotype for each polymorphism.
Recessive model column shows Fisher’s test results obtained by comparing the number of individuals with homozygous
genotype against the sum of individuals with another homozygous or heterozygous genotype for each polymorphism.
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Genotype
Genotypeprediction tools and statistical evaluation of allele/genotype
distribution between groups are to be expected.
The allele distributions of three polymorphisms already
described  in  previous  studies  related  to  Alport  syndrome
(D326Y [29] in COL4A3 and M1327V [22,33] and F1644F
[33] in COL4A4) were significant for the KC patient cohort.
We cannot speculate that these polymorphisms in any way
alter the collagen assembly or promote KC disease, although




comparison p-value OR RR
G43R 127GG GG versus CC NC NC NC
  127CC GC versus GG 1.0000    
  127GC GC versus CC NC NC NC
P141L 422CC CC versus TT 0.0325 7.138 4.849
  422TT CT versus CC 0.0262 1.971 1.447
  422CT CT versus TT 0.0022 14.069 7.016
E162G 485AA AA versus GG 0.2550    
  485GG AG versus AA 0.4790    
  485AG AG versus GG 0.2289    
D326Y 976GG GG versus TT <0.0001 52.364 21.926
  976TT GT versus GG <0.0001 0.0875 0.1905
  976GT GT versus TT 0.2520    
H451R 1352AA AA versus GG NC NC NC
  1352GG AG versus AA 1.0000    
  1352AG AG versus GG NC NC NC
G484G 1452GG GG versus AA NC NC NC
  1452AA GA versus GG 0.8306    
  1452GA GA versus AA NC NC NC
P574L 1721CC CC versus TT 0.3248    
  1721TT CT versus CC 0.8825    
  1721CT CT versus TT 0.1686    
G895G 2685AA AA versus CC 0.0352 0.3158 0.5667
  2685CC AC versus AA 0.6933    





comparison p-value OR RR
P482S 1444CC CC versus TT 0.1857    
  1444TT CT versus CC 0.0726    
  1444CT CT versus TT 0.0061 0.3056 0.5370
G545A 1634GG GG versus CC NC NC NC
  1634CC GC versus GG 0.8130    
  1634GC GC versus CC NC NC NC
G789G 2367AA AA versus TT 0.4033    
  2367TT AT versus AA 0.6270    
  2367AT AT versus TT 0.3684    
M1327V 3979AA AA versus GG <0.0001 0.0853 0.1535
  3979GG AG versus AA <0.0001 13.683 7.030
  3979AG AG versus GG 0.6567    
V1516V 4548AA AA versus GG 0.2864    
  4548GG AG versus AA 0.1940    
  4548AG AG versus GG 0.0153 2.373 1.716
F1644F 4932CC CC versus TT 0.0021 3.399 2.240
  4932TT CT versus CC 0.3283    
  4932CT CT versus TT 0.0148 2.561 1.916
Significant differences are shown in bold. Statistics were based on genotype representation shown in Table 5 (104 keratoconus
patients and 157 controls). NC- not calculated, Genotype: Genotypes found representing each polymorphism in cases and
controls. Fisher’s exact test was used for statistics. Genotype comparison: genotypes compared against each other. Differences
between genotypes are significant when two-sided p-value (p-value) is less than 0.05. OR: Odds ratio, RR: relative risk. OR
and RR are shown only for genotypes with significant differences (p-value less than 0.05).
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substitution could have an effect on the structure and function
of the protein. The other two alleles significant for KC patients
were found in the COL4A4 gene, resulting in one missense
and  one  silent  alteration  (3979G,  M1327V  and  4932C,
F1644F), although substitution is predicted to be benign and
tolerated. When comparing genotypes, we discovered specific
genotypes  related  to  KC  patients  even  though  the  allele
distribution was not significantly different. Under different
models  (dominant,  recessive,  and  additive),  we  found  a
significant representation of the following genotypes: 422CC,
422TT,  422CT,  and  2685CC  in  COL4A3  and  1444TT,
4548AA, and 4548AG in COL4A4. The prediction tools used
showed the possibility that some of the substitution resulting
from these genotypes could be damaging (Table 7). In order
to conclude whether genotype representations are specific for
our  population  or  are  in  fact  disease  specific,  different
populations should be examined and data compared.
In view of the lack of mutations, we could speculate that
mutations in collagen type IV (COL4A3 and COL4A4 genes)
are not involved in KC disease and that other genes and factors
are  involved  in  the  pathogenesis  of  this  disorder,  but
functional assay would be required to clarify this speculation.
This study established that significant relationships between
KC  patients  and  different  genotypes  in  COL4A3  and
COL4A4 exist, so the significance of the genotypes should be
established by further analysis that would involve different
populations.  There  is  a  possibility  that  some  of  the
polymorphisms could be related to KC, a feature that could
be used in helping the determination of the molecular genetics
of the disease.
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